Much cheaper, almost as good: Decrementally cost-effective medical innovation

Annals of Internal Medicine

Volumn 151, Issue 9, 2009, Pages 662-667

  Nelson, Aaron L ^a   Cohen, Joshua T ^c   Greenberg, Dan ^b   Kent, David M ^c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; OMEPRAZOLE;

ARTIFICIAL KIDNEY; AUTOMATED EXTERNAL DEFIBRILLATOR; AUTOMUTILATION; BEHAVIOR THERAPY; CANCER HORMONE THERAPY; CHRONIC KIDNEY FAILURE; COGNITIVE THERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEFIBRILLATOR; ELECTROCONVULSIVE THERAPY; HEALTH CARE COST; HEART DEATH; HEMODIALYSIS; HERNIOPLASTY; HOME CARE; HUMAN; IMPLANTATION; INGUINAL HERNIA; INSTRUMENT STERILIZATION; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR DEPRESSION; MEDIASTINOSCOPY; MEDICAL LITERATURE; MEDICAL TECHNOLOGY; NECK PAIN; PERCUTANEOUS CORONARY INTERVENTION; PHYSIOTHERAPY; PRIORITY JOURNAL; PROBLEM SOLVING; PROSTATE CANCER; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; RECYCLING; REFLUX ESOPHAGITIS; REVIEW; STOMACH FUNDOPLICATION; SUDDEN DEATH; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; WATCHFUL WAITING;

COST-BENEFIT ANALYSIS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY, MEDICAL;

EID: 70450221024     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.1059/0003-4819-151-9-200911030-00011     Document Type: Review

References (51)

1. Orszag PR, Ellis P. The challenge of rising health care costs - a view from the Congressional Budget Office. N Engl J Med. 2007;357:1793-1795 [PMID: 17978287] (Pubitemid 350044798)
2. Bodenheimer T. High and rising health care costs. Part 2: technologic innovation. Ann Intern Med. 2005;142:932-937 [PMID: 15941701]
3. McNeil BJ. Shattuck Lecture - Hidden barriers to improvement in the quality of care. N Engl J Med. 2001;345:1612-1620 [PMID: 11757509]
4. Newhouse JP. Medical care costs: how much welfare loss? J Econ Perspect. 1992;6:3-21. [PMID: 10128078]
5. Okunad AA, Murthy VN. Technology as a 'major driver' of health care costs: a cointegration analysis of the Newhouse conjecture. J Health Econ. 2002;21: 147-159 [PMID: 11852912]
6. Baker L, Birnbaum H, Geppert J, Mishol D, Moyneur E. The relationship between technology availability and health care spending. Health Aff (Millwood). 2003;Suppl Web Exclusives:W3-537-551 [PMID: 15506158]
7. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332: 699-703. [PMID: 16495332] (Pubitemid 44365687)
8. Dowie J. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. Health Econ. 2004;13:453-459 [PMID: 15127425] (Pubitemid 38660394)
9. Kent DM, Fendrick AM, Langa KM. New and dis-improved: on the evaluation and use of less effective, less expensive medical interventions. Med Decis Making. 2004;24:281-286 [PMID: 15155017]
10. O'Brien BJ, Gertsen K, Willan AR, Faulkner LA. Is there a kink in consumers' threshold value for cost-effectiveness in health care? Health Econ. 2002; 11:175-180 [PMID: 11921315]
11. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med. 1998; 339:380-386 [PMID: 9691106]
12. O'Brien BJ, Goeree R, Gafni A, Torrance GW, Pauly MV, Erder H, et al. Assessing the value of a new pharmaceutical. A feasibility study of contingent valuation in managed care. Med Care. 1998;36:370-384 [PMID: 9520961]
13. Carthy T, Chilton S, Covey J, Hopkins L, Jones-Lee M, Loomes G, et al. On the contingent valuation of safety and the safety contigent valuation: part 2 - the CV/SC "chained" approach. J Risk Uncertain. 1998;17:187-213.
14. UKATT Research Team. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331:544. [PMID: 16150765]
15. Byford S, Knapp M, Greenshields J, Ukoumunne OC, Jones V, Thompson S, et al; POMACT Group. Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychol Med. 2003;33:977-986 [PMID: 12946082]
16. Coupé VM, Veenhof C, van Tulder MW, Dekker J, Bijlsma JW, Van den Ende CH. The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee. Ann Rheum Dis. 2007;66:215-221 [PMID: 16880195] (Pubitemid 46226057)
17. Erstad BL. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding. Crit Care Med. 2004;32:1277-1283 [PMID: 15187506]
18. Esnaola NF, Lazarides SN, Mentzer SJ, Kuntz KM. Outcomes and costeffectiveness of alternative staging strategies for non-small-cell lung cancer. J Clin Oncol. 2002;20:263-273 [PMID: 11773178]
19. Garside R, Stein K, Wyatt K, Round A, Pitt M. A cost-utility analysis of microwave and thermal balloon endometrial ablation techniques for the treatment of heavy menstrual bleeding. BJOG. 2004;111:1103-1114 [PMID: 15383113] (Pubitemid 39319270)
20. Gómez-Outes A, Rocha E, Martínez-González J, Kakkar VV. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics. 2006;24:81-92. [PMID: 16445305] (Pubitemid 43197233)
21. Honkanen LA, Mushlin AI, Lachs M, Schackman BR. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations? J Am Geriatr Soc. 2006;54:1658-1665 [PMID: 17087691]
22. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287: 2382-2390 [PMID: 11988059]
23. Kozel FA, George MS, Simpson KN. Decision analysis of the costeffectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. CNS Spectr. 2004; 9:476-482 [PMID: 15162090]
24. Manca A, Epstein DM, Torgerson DJ, Klaber Moffett JA, Coulton S, Farrin AJ, et al. Randomized trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: cost-effectiveness analysis. Int J Technol Assess Health Care. 2006;22:67-75. [PMID: 16673682] (Pubitemid 43376241)
25. Manns BJ, Taub K, Richardson RM, Donaldson C. To reuse or not to reuse? An economic evaluation of hemodialyzer reuse versus conventional singleuse hemodialysis for chronic hemodialysis patients. Int J Technol Assess Health Care. 2002;18:81-93. [PMID: 11987444] (Pubitemid 34408531)
26. McKay A, Kutnikoff T, Taylor M. A cost-utility analysis of treatments for malignant liver tumours: a pilot project. HPB (Oxford). 2007;9:42-51. [PMID: 18333112] (Pubitemid 46992941)
27. Nietert PJ, Silverstein MD, Mokhashi MS, Kim CY, Glenn TF, Marsi VA, et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc. 2003;57:311-318 [PMID: 12612508]
28. O'Connor JB, Singer ME, Imperiale TF, Vaezi MF, Richter JE. The costeffectiveness of treatment strategies for achalasia. Dig Dis Sci. 2002;47:1516-1525 [PMID: 12141811]
29. Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med. 2005;7:380-389 [PMID: 16024969]
30. Palmer S, Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. J Pers Disord. 2006;20:466-481 [PMID: 17032159] (Pubitemid 44580880)
31. Pyne JM, Smith J, Fortney J, Zhang M, Williams DK, Rost K. Costeffectiveness of a primary care intervention for depressed females. J Affect Disord. 2003;74:23-32. [PMID: 12646296] (Pubitemid 36324474)
32. Romagnuolo J, Meier MA, Sadowski DC. Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model. Ann Surg. 2002;236:191-202. [PMID: 12170024] (Pubitemid 34809538)
33. Serrano-Blanco A, Pinto-Meza A, Suárez D, Peñarrubia MT, Haro JM; ETAPS Group (Efectivitat del Tractament antidepressiu en Atenció Primària de Salut). Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia. Acta Psychiatr Scand Suppl. 2006:39-47. [PMID: 17087814] (Pubitemid 44707081)
34. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology. 2002;122:1270-1285 [PMID: 11984514]
35. Stroupe KT, Manheim LM, Luo P, Giobbie-Hurder A, Hynes DM, Jonasson O, et al. Tension-free repair versus watchful waiting for men with asymptomatic or minimally symptomatic inguinal hernias: a cost-effectiveness analysis. J Am Coll Surg. 2006;203:458-468 [PMID: 17000388] (Pubitemid 44416247)
36. Struijs PA, Korthals-de Bos IB, van Tulder MW, van Dijk CN, Bouter LM, Assendelft WJ. Cost effectiveness of brace, physiotherapy, or both for treatment of tennis elbow. Br J Sports Med. 2006;40:637-43; discussion 643. [PMID: 16687482]
37. U-King-Im JM, Hollingworth W, Trivedi RA, Cross JJ, Higgins NJ, Graves MJ, et al. Cost-effectiveness of diagnostic strategies prior to carotid endarterectomy. Ann Neurol. 2005;58:506-515 [PMID: 16178014] (Pubitemid 41377213)
38. Valenzuela MT, Jacobs RJ, Arteaga O, Navarrete MS, Meyerhoff AS, Innis BL. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine. 2005;23:4110-4119 [PMID: 15964479] (Pubitemid 40823054)
39. Weintraub WS, Mahoney EM, Zhang Z, Chu H, Hutton J, Buxton M, et al. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart. 2004;90:782-788 [PMID: 15201249] (Pubitemid 38813640)
40. You JH, Sahota DS, MoYuen P. A cost-utility analysis of hysterectomy, endometrial resection and ablation and medical therapy for menorrhagia. Hum Reprod. 2006;21:1878-1883 [PMID: 16585125] (Pubitemid 44028264)
41. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008;358: 661-663 [PMID: 18272889]
42. Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, et al; REFLUX Trial Group. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ. 2008;337:a2664. [PMID: 19074946]
43. Cram P, Vijan S, Wolbrink A, Fendrick AM. The impact of including passive benefits in cost-effectiveness analysis: the case of automated external defi- brillators on commercial aircraft. Value Health. 2003;6:466-473 [PMID: 12859588] (Pubitemid 36929735)
44. Wagmiller JA, Griggs JJ, Dick AW, Sahasrabudhe DM. Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs. J Oncol Pract. 2006;2:57-66.
45. Hrung JM, Langlotz CP, Orel SG, Fox KR, Schnall MD, Schwartz JS. Cost-effectiveness of MR imaging and core-needle biopsy in the preoperative work-up of suspicious breast lesions. Radiology. 1999;213:39-49. [PMID: 10540638]
46. Kunz K, Kuppermann M, Bowe T, Williamson A, Mazonson P. Protein A immunoadsorption column versus splenectomy in the treatment of steroidresistant immune thrombocytopenic purpura. A cost-effectiveness analysis. Int J Technol Assess Health Care. 1996;12:436-449 [PMID: 8840664] (Pubitemid 26295786)
47. Tan MC, Marra CA, Sadatsafavi M, Marra F, Morán-Mendoza O, Moadebi S, et al. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia. Value Health. 2008;11:842-852 [PMID: 18489519]
48. Hayward RA, Heisler M, Adams J, Dudley RA, Hofer TP. Overestimating outcome rates: statistical estimation when reliability is suboptimal. Health Serv Res. 2007;42:1718-1738 [PMID: 17610445] (Pubitemid 47024840)
49. Arrow KJ. Uncertainty and the welfare economics of medical care. American Economic Review. 1963;53:941-973
50. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med. 1997;337:853-856 [PMID: 9295246] (Pubitemid 27391640)
51. Cohen JT, Neumann PJ. What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits). Health Aff (Millwood). 2007;26:636-646 [PMID: 17485738]